Price to sales forward of AngioDynamics, Inc. – NASDAQ:ANGO
This article provides financial information for AngioDynamics, Inc. (NASDAQ: ANGO), specifically its forward price-to-sales ratio. It lists the company's stock market data and indicates that the market is currently closed with no trades. The core content appears to be a data point for the "Price to sales forward" for which no specific value is given in this excerpt.
Price to sales forward of AngioDynamics, Inc. – LS:A0B9A5
This article provides financial data for AngioDynamics, Inc. (A0B9A5) on TradingView, specifically focusing on its forward price-to-sales ratio. It lists market information, financial overviews, and other technical and fundamental data points available for the company.
Press Release: AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
AngioDynamics (NASDAQ: ANGO) announced it will report its fiscal 2026 fourth quarter and full-year financial results on Tuesday, July 14, 2026, before the market opens. Management will host a conference call and webcast at 8:00 a.m. EDT to discuss the results and provide a business update. A replay of the webcast will be available for 90 days.
AngioDynamics sets July 14 call for fiscal 2026 results
AngioDynamics announced it will report its fiscal year 2026 fourth quarter and full-year financial results on July 14, 2026, before market open. The company's management will host a conference call at 8:00 AM ET on the same day to discuss these results. The call details and webcast information are provided for investors and interested parties.
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
AngioDynamics has received FDA Investigational Device Exemption (IDE) approval to begin the RELIEF study, evaluating its NanoKnife System for treating benign prostatic hyperplasia (BPH). This feasibility study will assess the irreversible electroporation (IRE) technology as a minimally invasive treatment for lower urinary tract symptoms associated with BPH, enrolling 40 subjects across five clinical sites in the U.S. The study aims to gather initial safety and effectiveness data to support IRE as a tissue-sparing solution for BPH, evaluating improvements in urinary symptoms and monitoring for five years.
AngioDynamics, Inc. Actuals & Estimates (NASDAQ:ANGO)
This article provides an in-depth financial overview of AngioDynamics, Inc. (NASDAQ:ANGO), including its stock performance, analyst estimates, historical prices, market capitalization, earnings, and revenue. It highlights ANGO's recent stock price increase, upcoming earnings report, and current financial metrics for investors.
ANGO Forecast — Price Target — Prediction for 2027
This article provides a forecast for AngioDynamics, Inc. (ANGO) stock, including analyst price targets, past performance, and key financial metrics. It highlights that AngioDynamics is expected to release its next earnings report on July 21, 2026, and details previous earnings and revenue figures. The company's current stock price, market capitalization, and volatility are also discussed, along with a "strong buy" technical analysis rating.
AngioDynamics Port Catheter Lawsuit Claims Woman’s SmartPort Implants Caused Multiple Infections
A Georgia woman has filed a lawsuit against AngioDynamics and Navilyst Medical, alleging that two of their SmartPort implants caused her to suffer multiple infections, requiring repeated surgeries. The lawsuit claims that the port catheters were defectively designed and manufactured, increasing the risk of bacterial growth and other serious complications. This case joins numerous other AngioDynamics port catheter lawsuits consolidated in a federal multidistrict litigation.
AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for AngioDynamics Inc (ANGO), noting its current valuation score of 7.26, which ranks 164th in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -16.31, which is significantly below its recent high and above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
AngioDynamics Inc (ANGO) Institutional Confidence
AngioDynamics Inc (ANGO) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is currently 93.94%, a decrease of 11.97% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 3.06 million shares, representing 7.63% of outstanding shares.
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study
AngioDynamics (ANGO) has received FDA IDE approval for its RELIEF study, which will evaluate the NanoKnife System's irreversible electroporation (IRE) technology for treating benign prostatic hyperplasia (BPH). This study expands the NanoKnife's clinical applications beyond oncology and targets a significant market, potentially enhancing its long-term growth and adoption. Despite a slight dip in share price post-announcement, the development strengthens ANGO's market position and addressable market.
AngioDynamics receives FDA approval for RELIEF clinical study
AngioDynamics has received FDA approval for an Investigational Device Exemption to commence its RELIEF clinical study. This study will evaluate the NanoKnife System for treating lower urinary tract symptoms in men with benign prostatic hyperplasia, aiming to generate safety and effectiveness data. The prospective, single-arm trial will enroll 40 subjects across five U.S. clinical sites and is intended to lay the groundwork for future clinical development of this non-thermal ablation technology in urologic conditions.
AngioDynamics wins FDA okay to test NanoKnife in BPH patients
AngioDynamics (NASDAQ: ANGO) has received FDA approval for an Investigational Device Exemption (IDE) to initiate the RELIEF study. This feasibility study will evaluate the company's NanoKnife System, which uses irreversible electroporation (IRE) technology, as a minimally invasive treatment for benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms. The study aims to gather safety and effectiveness data for IRE as a tissue-sparing option for the millions of men affected by BPH.
AngioDynamics receives FDA approval for BPH treatment study
AngioDynamics (NASDAQ:ANGO) has received FDA approval for an Investigational Device Exemption application to commence its RELIEF study, investigating the use of its NanoKnife System for treating benign prostatic hyperplasia (BPH). The study will evaluate the system's irreversible electroporation technology to treat lower urinary tract symptoms in men with BPH. This comes as the company continues to make strategic moves, including exceeding Q3 revenue expectations and filing a patent infringement lawsuit.
AngioDynamics Inc (ANGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for AngioDynamics Inc (ANGO), detailing its regional revenue contributions. As of the latest update, the data shows that the United States accounts for 85.79% ($67.28M) of the company's revenue, while International operations contribute 14.21% ($11.14M). The segment-specific revenue and profit contribution data have not yet been disclosed by the company.
AngioDynamics Inc (ANGO) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for AngioDynamics Inc (ANGO), highlighting a current earnings forecast score of 8.00 and an average price target of $17.00 from four analysts. It details expected future EPS and revenue figures, along with a peer comparison in the Healthcare Equipment & Supplies industry.
Xcela Port Lawsuit Claims AngioDynamics Catheter Caused Thrombosis
A product liability lawsuit has been filed against AngioDynamics Inc. and Navilyst Medical Inc. by a Florida woman, Kimberly Daniels, alleging that a defective Xcela port catheter caused her to suffer from a dangerous occlusive thrombus. The lawsuit claims that the companies were aware of issues like thrombosis and infections linked to catheter deterioration for years but continued to market the devices as safe. This case will be centralized with nearly 400 other similar lawsuits against AngioDynamics, with bellwether trials expected to inform potential settlement outcomes.
AngioDynamics | SCHEDULE 13G/A: Others
This entry indicates a SCHEDULE 13G/A filing for AngioDynamics, related to insider transactions classified under "Others." The document title is simply "Document," suggesting the filing contains the pertinent details.
ANGO News | ANGIODYNAMICS INC (NASDAQ:ANGO)
This article provides a list of recent news and analysis for AngioDynamics Inc. (NASDAQ: ANGO), detailing earnings reports, new Medicare coverage for its NanoKnife IRE system, and upcoming conference presentations. It also includes analyst opinions on the stock's potential upside.
Port Catheter Thrombosis Lawsuit Claims Defective AngioDynamics Xcela Device Caused Injury
A Nevada woman has filed a product liability lawsuit against AngioDynamics Inc., Navilyst Medical Inc., and PFM Medical Inc., alleging that a defective AngioDynamics Xcela port catheter caused thrombosis in her jugular vein. The lawsuit claims that the barium sulfate material used in the catheter weakens the device over time, leading to complications like thrombosis, and that the manufacturers failed to warn about these risks. This case will join an existing multidistrict litigation (MDL) for AngioDynamics port catheter lawsuits.
ANGO Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for AngioDynamics Inc (ANGO) as of May 29, 2026. It highlights a "Sell" technical sentiment based on aggregating 14 technical signals, with 8 indicating sell and 6 indicating buy. The analysis details momentum indicators, support and resistance levels, and moving averages, concluding that ANGO is trading below its 60-day and 200-day moving averages.
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO)
This article highlights bullish analyst sentiments for three healthcare stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO), and NeuroPace (NPCE). Goldman Sachs maintained a Buy rating on Biohaven with a $25.00 price target, while Canaccord Genuity held a Buy rating on AngioDynamics with a $16.00 target. Lake Street reiterated a Buy rating on NeuroPace, setting a price target of $20.00, indicating significant upside potential for these companies.
Medicare contractor to cover NanoKnife prostate and liver cancer IRE procedure
AngioDynamics (NASDAQ: ANGO) announced that Palmetto GBA, a Medicare contractor, issued a final Local Coverage Determination (LCD L40205) for its NanoKnife System, covering irreversible electroporation (IRE) procedures for favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver, effective July 5, 2026. This decision builds upon the Category I CPT codes for IRE procedures activated on January 1, 2026, advancing reimbursement infrastructure and patient
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AngioDynamics, Inc. announced its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 9:20 a.m. (ET). A live webcast will be available on the company's website. AngioDynamics is a medical technology company focused on vascular systems, cancer treatment, and improving patient quality of life.
Webcast set for AngioDynamics talk at Goldman Sachs health event
AngioDynamics (NASDAQ: ANGO) announced that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 9:20 a.m. ET. A live webcast of the presentation will be available through the "Investors" section of the company's website and for replay afterward. AngioDynamics is a medical technology company focused on vascular health and cancer treatment.
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 9:20 a.m. ET. A live webcast of the presentation will be available for replay on the "Investors" section of the company's website. AngioDynamics is a medical technology company focused on vascular systems, cancer treatment, and improving patient quality of life.
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 9:20 a.m. (ET). A live webcast of the event will be available on the Investors section of the Company's website, with a replay accessible afterward. AngioDynamics is a medical technology company focused on vascular health and cancer treatment options.
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AngioDynamics, Inc. announced that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 9:20 a.m. ET. A live webcast of the presentation will be available on the company's website under the "Investors" section. AngioDynamics is a medical technology company focused on improving vascular health and cancer treatment.
ANGO Stock Price, Quote & Chart | ANGIODYNAMICS INC (NASDAQ:ANGO)
This article provides a comprehensive overview of AngioDynamics Inc. (NASDAQ: ANGO) stock, including its current price, historical performance, key statistics, and analyst forecasts. It details the company's technical and fundamental ratings, recent earnings reports, and highlights its position within the Health Care Equipment industry, alongside competitive analysis.
Understanding Momentum Shifts in (ANGO)
The article analyzes Angiodynamics Inc. (NASDAQ: ANGO), highlighting strong sentiment across all horizons and an exceptional 55.3:1 risk-reward setup. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal data indicating strong signals across near-term, mid-term, and long-term horizons, supported by various price levels.
Point72 (ANGO) reports 3.18M shares, 7.7% stake via Point72 Associates
Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a beneficial ownership of 3,181,829 shares in AngioDynamics (ANGO), representing a 7.7% stake as of March 31, 2026. These shares are held through Point72 Associates, an investment fund managed by Point72 Asset Management, and involve shared voting and dispositive power. The filing clarifies the control relationships among the reporting entities, with Steven A. Cohen controlling both Point72 Asset Management and Point72 Capital Advisors Inc., but explicitly states that the reporting persons do not directly own these shares.
SmartPort Surgery Lawsuit Claims AngioDynamics Catheter Fractured Inside Woman’s Body
A Missouri woman has filed a product liability lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that an AngioDynamics SmartPort catheter fractured inside her body, requiring surgical removal of a broken segment from major veins near her heart. The lawsuit claims the SmartPort was defectively designed and manufactured, and that the company concealed a higher failure rate compared to similar devices. This case joins numerous other AngioDynamics lawsuits consolidated in a multidistrict litigation, raising similar allegations against the manufacturers for alleged negligence, design defects, and failure to warn.
AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer
AngioDynamics reported durable oncologic control in a study of its NanoKnife system for intermediate-risk prostate cancer. The study showed a disease-free survival rate of 96% at two years, with minimal impact on urinary and sexual function. These positive results support the NanoKnife system's potential as a treatment option for prostate cancer patients.
AngioDynamics reports 24-month data from prostate cancer trial
AngioDynamics announced positive 24-month results from its PRESERVE pivotal trial for the NanoKnife System in treating intermediate-risk prostate cancer, showing 94.4% of patients completed the assessment with no new treatment failures. The company's stock shows significant upside potential according to analysts, despite being unprofitable, and the NanoKnife System continues to demonstrate its effectiveness through irreversible electroporation technology. Recent financial reports also indicate AngioDynamics surpassed Q3 2026 earnings and revenue expectations.
Angiodynamics Announces Two-Year Preserve Trial Data Demonstrating Durable Nanoknife Ire System Outcomes In Intermediate-Risk Prostate Cancer
Angiodynamics announced positive two-year data from its Preserve Trial, demonstrating durable outcomes for patients with intermediate-risk prostate cancer treated with the NanoKnife IRE System. This news, reported by Refinitiv, highlights the potential long-term efficacy of the NanoKnife system in this patient population. The article is very short, indicating a brief breaking news announcement.
Prostate cancer trial sees 0 new failures with NanoKnife at 2 years
AngioDynamics (NASDAQ: ANGO) announced positive two-year results from its PRESERVE pivotal trial for the NanoKnife System in treating intermediate-risk prostate cancer. The data showed sustained oncologic control and safety, with no new treatment failures between 12 and 24 months and 97% of patients having PSA levels below baseline. These findings reinforce the NanoKnife System as a durable and effective focal therapy option.
AngioDynamics introduces Soft Vu Angiographic Catheters with over 50 tip shapes
AngioDynamics has launched its new Soft Vu Angiographic Catheters, providing medical professionals with over 50 tip shapes to address diverse clinical needs and anatomical challenges. This introduction aims to enhance procedural flexibility and is a direct result of ongoing physician-driven innovation, incorporating feedback gathered from events like the SIR conference. The company emphasizes its commitment to integrating medical professional insights into product development.
136,333 Shares in AngioDynamics, Inc. $ANGO Bought by D.A. Davidson & CO.
D.A. Davidson & CO. has acquired a new stake of 136,333 shares, valued at approximately $1.75 million, in AngioDynamics, Inc. during the fourth quarter. This acquisition represents about 0.33% of the company's total shares, with institutional investors collectively owning 89.43%. Despite a consensus "Moderate Buy" rating with an $18.67 target, analyst sentiment is mixed, including recent downgrades and a price target reduction by Canaccord Genuity, while Weiss Research reiterated a "sell" rating.
AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Up 18.7% in April
AngioDynamics, Inc. (NASDAQ:ANGO) saw an 18.7% increase in short interest during April, reaching 2,161,213 shares, which represents about 5.6% of its shares sold short. This implies a 3.3 days-to-cover ratio based on average daily trading volume. Despite beating recent quarterly estimates, the company remains unprofitable, though analysts maintain a "Moderate Buy" rating with an average price target of $18.67.
AngioDynamics Catheter Lawsuit Claims SmartPort Device Embedded in Jugular Vein, Caused Embolism
A product liability lawsuit has been filed against AngioDynamics Inc. and Navilyst Medical Inc., alleging that a SmartPort catheter became embedded in a Michigan woman's jugular vein, causing an embolism and other complications. The complaint claims that the device was defectively designed due to the inclusion of barium sulfate, which may degrade the catheter material over time and lead to microfractures and device failure. This lawsuit joins over 300 similar AngioDynamics cases centralized in a multidistrict litigation, with bellwether trials expected to begin after initial selections in June.
Discipline and Rules-Based Execution in ANGO Response
Quantitative Research Desk provides an analysis of Angiodynamics Inc. (NASDAQ: ANGO), noting weak near-term sentiment that could shift mid and long-term outlooks. The report highlights a mid-channel oscillation pattern and an exceptional 53.7:1 risk-reward short setup. It also outlines three distinct trading strategies generated by AI models for different risk profiles.
Weber Capital Management LLC ADV Invests $17.98 Million in AngioDynamics, Inc. $ANGO
Weber Capital Management LLC ADV has made a significant investment of $17.98 million in AngioDynamics, Inc. (NASDAQ:ANGO), acquiring over 1.4 million shares which now represent 17% of the fund's holdings and 3.40% of AngioDynamics. The medical instruments supplier, despite slightly beating quarterly earnings estimates, remains unprofitable with a negative net margin. Analyst ratings for AngioDynamics are mixed, ranging from "strong-buy" to "sell," with an average target price of $18.67.
FY2026 EPS Estimates for AngioDynamics Increased by Analyst
Zacks Research has increased its FY2026 EPS estimate for AngioDynamics (NASDAQ:ANGO) from ($0.26) to ($0.23), while maintaining a "Hold" rating on the stock. Despite a "Moderate Buy" consensus rating from analysts, with various "Strong Buy," "Buy," "Hold," and "Sell" assignments, the average target price is $18.67. AngioDynamics recently surpassed earnings expectations, reporting ($0.07) EPS against an estimated ($0.11), with revenues of $78.42 million.
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag
This article provides a quantitative snapshot of stock performance, highlighting J. Jill and AngioDynamics as strong buys. Conversely, INmune Bio and Terrestrial Energy are identified as lagging in the current market analysis. The report likely details the factors contributing to these classifications through quantitative metrics.
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of "Moderate Buy" by Analysts
AngioDynamics, Inc. (NASDAQ:ANGO) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $18.67. Institutional investors, including Kotler Kevin and Weber Capital, have significantly increased their positions, with overall institutional ownership at 89.43%. The company recently reported Q4 EPS of ($0.07) and revenue of $78.42 million, exceeding analyst estimates.
AngioDynamics files patent lawsuit against Endovascular Engineering
AngioDynamics has filed a patent infringement lawsuit against Endovascular Engineering (E2) in federal court in Delaware. The lawsuit alleges that E2's Hēlo Thrombectomy System infringes on AngioDynamics' patents related to self-expanding funnel technology for thrombi and emboli removal. AngioDynamics is seeking damages and equitable relief, emphasizing its commitment to protecting its intellectual property.
AngioDynamics Files Patent Suit to Protect Thrombectomy Technology
AngioDynamics has filed a patent infringement lawsuit against Endovascular Engineering, Inc. in the U.S. District Court for the District of Delaware. The suit alleges that E2’s Hēlo Thrombectomy System infringes upon AngioDynamics’ patents, specifically its proprietary self-expanding funnel technology. AngioDynamics is seeking damages and equitable relief to protect its intellectual property and competitive position in the vascular intervention market.
AngioDynamics files patent lawsuit against Endovascular Engineering
AngioDynamics has filed a patent infringement lawsuit against Endovascular Engineering (E2) over its Hēlo Thrombectomy System, alleging it uses AngioDynamics' proprietary self-expanding funnel technology. This comes as AngioDynamics recently reported better-than-expected Q3 2026 earnings and received a "Buy" rating from Freedom Broker, although Canaccord lowered its price target due to margin pressures. The medical device company seeks damages and equitable relief to protect its intellectual property.
[8-K] ANGIODYNAMICS INC Reports Material Event
AngioDynamics, Inc. (ANGO) has filed an 8-K report announcing a patent infringement lawsuit against Endovascular Engineering, Inc. (E2). The lawsuit alleges that E2's Hēlo Thrombectomy System infringes on AngioDynamics' patents relating to its self-expanding funnel technology, seeking damages and equitable relief. AngioDynamics stated its commitment to vigorously protecting its intellectual property rights to support innovation and patient care.
Physician insights guide AngioDynamics new innovation push at SIR 2026
AngioDynamics is intensifying its focus on physician-led innovation, drawing significant guidance from discussions held at SIR 2026 in Toronto. The company plans to integrate physician input into its R&D strategy, with specific project details expected in the coming months. This initiative builds on recent product launches and talent investments, underscoring AngioDynamics' commitment to advancing healthcare through practitioner collaboration.
